2013 has been a great year in the world of pharmaceutical and biotech R&D. While we are still facing mounting productivity challenges, many have come to understand that any single company – no matter how committed to patients – can overcome these challenges on their own.
Open and collaborative approaches are creating exciting waves of change and opportunity on a global scale. Looking into 2014, how are external forces shaping solutions for patients? And how can we, collectively, propel our industry to fast forward?
Hui Cai, Forum Chair; VP of Corporate Alliances and Head of Communications, WuXi AppTec
Moderator: David Flores, Co-Founder, President & CEO, Biocentury
George Golumbeski, SVP of Business Development, Celgene
Andrew Schwab, Managing Partner, 5AM Ventures
Morton Meyerson, Founder, Chairman & CEO, 2M Companies; Chairman & CEO, 2M BioTech
Moderator: Richard Soll, SVP of Integrated Services and Head of Corporate Alliances, WuXi AppTec
Emmanuel Canet, President of R&D, Servier
Martin Mackay, EVP and Global Head of R&D, Alexion Pharmaceuticals
Edward Hu, COO and CFO, WuXi AppTec
Moderator: Greg Scott, Founder and CEO, ChinaBio
Jonathan Wang, Senior Manager Partner, Orbimed Asia
Jie D’Elia, Executive Director of Business Development, BMS
Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals
Dr. Hui Cai joined WuXi AppTec in 2009 as Vice President of Business Development, and is currently Vice President of Corporate Alliances and Head of PR and Corporate Communications.
Mr. David Flores has devoted more than two decades to developing information products for biotechnology executives and investors. He is a graduate of the University of California at Berkeley and holds an MBA from Stanford University.
Dr. George Golumbeski is currently Senior Vice President of Business Development for Celgene Corporation, where he is responsible for the full array of business development activities (identification & evaluation of opportunities, structuring & negotiating transactions, in-licensing, M&A, outlicensing, and alliance management).
Mr. Andrew Schwab is a Founder and Managing Partner of 5AM Ventures.Prior to founding 5AM in 2002, Mr. Schwab was a Principal at Bay City Capital. At 5AM, he has led the firm’s investments in and served on the Boards of Directors of Biodesy, Cleave, DVS, Flexion, Ikaria, Ilypsa (acquired by Amgen), Miikana (acquired by EntreMed), Panomics (acquired by Affymetrix), RuiYi, Synosia (acquired by Biotie) and Viveve.
Mr. Morton Meyerson is the Founder, Chairman and CEO of 2M Companies, a full service holding company for a family office and foundation. He is also Chairman and CEO of 2M BioTech, a drug development company leveraging a broad network of expertise in drug development, financing, patent protection, startup development, marketing and communications.
Dr. Richard Soll is SVP of Integrated Services and Head of Corporate Alliances at WuXi AppTec. In this capacity, Dr. Soll has advanced more than 30 programs across major target classes and therapeutic indications from hits through lead optimization campaigns to clinical candidates on behalf of WuXi collaborators.
Dr Emmanuel Canet was trained in France and then Canada, and has spent the majority of his industrial career with the group Servier where he has been the President of Research and Development since September 2007.
Dr. Martin Mackay joined Alexion in May 2013 as EVP and Global Head of Research & Development. In his role, Dr. Mackay is focused on significantly expanding Alexion’s global R&D organization, with a goal of accelerating the simultaneous development of multiple life-transforming drug candidates in debilitating and life-threatening ultra-rare disorders across a range of therapeutic areas.
Mr. Edward Hu is currently COO and CFO at WuXi AppTec. In this capacity, Mr. Hu provides vision and oversight of new business and capability building, operational efficiency, organizational growth, and to ensure company’s financial health. In addition, Mr. Hu is Head of WuXi Corporate Venture Fund, spearheading the fund’s investment strategy and portfolio management.
Mr. Greg Scott founded ChinaBio LLC in January 2007 to bring together Chinese and Western life science companies to better leverage China’s rapidly growing life science markets. ChinaBio works with U.S. and European companies seeking partnerships, acquisitions, novel technologies and funding in China.
With over 20 years of life sciences experience spanning VC, entrepreneurship and research, Dr. Jonathan Wang has cofounded OrbiMed Asia. Previously, he was a Partner at Legend Capital and General Manager at Burrill Greater China Group.
Dr. Jie D’Elia joined BMS in 2013 as an Executive Director of Business Development where she will serve as the global head of China strategic transactions. Prior to BMS, she was the Corporate Vice President of Business Development and Investor Relations at Simcere Pharmaceutical.
Dr Carl Firth is CEO and Founder of ASLAN Pharmaceuticals. Previously, he was Head of Asia Healthcare at Bank of America Merrill Lynch, supporting public and private financing of healthcare companies across the region and advising on M&A transactions.